[Seminar] Patent Strategies for AI Drug Discovery - Latest Patent Practices and Future Measures
- Patent applications and rights acquisition, inventor recognition, examination practices in Japan, the United States, and Europe -
Our company will hold a business seminar. 【Practical Insights Gained from the Seminar】 - Understanding inventions in AI drug discovery, timing of applications, and criteria for recognizing inventors - Designing experimental data, specifications, and claims based on requirements for inventiveness, description, and feasibility - Organizing examination practices and future patent strategies in Japan, the US, and Europe from the latest application and registration cases both domestically and internationally 【Target Industries and Departments】 - Intellectual property departments of pharmaceutical companies and biotech ventures - Drug discovery research and research and development departments - Planning and business development departments responsible for AI drug discovery and digital drug discovery - Intellectual property and legal personnel in AI and data analysis companies - Industry-academia collaboration and intellectual property personnel in universities and research institutions 【Seminar Details】 ■ Date and Time: October 23, 2026 (Friday) 13:30 - 16:00 (Doors open at 13:00) ■ Venue: JPI Conference Square ■ Address: 5-2-32 Minamiazabu, Minato-ku, Tokyo, Kowa Hiroo Building ■ Participation Method: In-person, live streaming, archived streaming ■ Instructor: Professor Hiroshi Kato, Nihon University Graduate School (Patent Attorney) *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
**Lecture Overview** In recent years, the rapid advancement of generative AI has led to the increasing use of AI in various stages of drug development, from drug discovery to clinical development and formulation. Research and development methods utilizing AI have diversified, including target exploration, virtual screening, molecular generation and optimization, antibody and peptide design, and toxicity prediction. On the other hand, there are challenges to the practical application of AI in drug discovery, such as data quality, reliability, and reproducibility. Furthermore, it is crucial to determine how to recognize new compounds and medical applications generated by AI as inventions and how to protect and utilize them through patents. This lecture will discuss the latest trends in drug development utilizing generative AI, covering topics such as patent applications, rights acquisition, inventor recognition, and examination practices in Japan, the U.S., and Europe, while considering future intellectual property strategies and practical challenges in AI drug discovery. **Lecture Topics** ■ Latest trends and challenges in drug development utilizing generative AI ■ Patent trends in drug development utilizing generative AI ■ Patent application strategies in AI drug discovery ■ Risks and considerations regarding patents and intellectual property in AI drug discovery ■ Patent examination and rights acquisition for inventions related to AI drug discovery ■ Analysis of registered patents and recent application cases in AI drug discovery ■ Related Q&A ■ Business card exchange and networking event (limited to in-person attendees)
Price information
【Participation Fee】 1 person: 37,810 yen (tax included) From 2 people onwards: 32,810 yen (tax included / same organization, simultaneous application) *For those affiliated with local public organizations, up to 2 people can register for 11,000 yen (tax included / venue and live streaming only / same participation format)
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
JPI Corporation (Japan Planning Institute) has been providing valuable information for executives and senior management involved in the execution of national policies and national projects, supporting the dissemination of state policies as a 'bridge of knowledge' between 'government', 'administration', and 'citizens' in the form of exclusive real seminars for participants for half a century, aiming to create national knowledge.
